Salemonline Journal

Upper Gastrointestinal (GI) Series Market is expected to grow at a CAGR of 4.5% By 2023, Global Industry Size, Share, Growth, Top Company Players, Regional Analysis

 Breaking News
  • No posts were found

Upper Gastrointestinal (GI) Series Market is expected to grow at a CAGR of 4.5% By 2023, Global Industry Size, Share, Growth, Top Company Players, Regional Analysis

August 25
11:09 2019
Upper Gastrointestinal (GI) Series Market is expected to grow at a CAGR of 4.5% By 2023, Global Industry Size, Share, Growth, Top Company Players, Regional Analysis

Upper Gastrointestinal (GI) Series Market
Global upper GI series market research report, by test types (the standard barium upper GI series & double-contrast upper GI series), by type of imaging material (barium swallow, barium meal, barium follow-through), by application (esophageal reflux, esophageal varices, ulcers, hiatal hernias & others), by end users (hospitals, clinics & laboratories and other) -Forecast till 2023

Upper Gastrointestinal (GI) Series Market Highlights

Upper GI series is a diagnostic procedure used to examine the abnormality or infection in GI tract. During this procedure, contrast media is administered to the patient and with the help of X-rays the radiograph is taken. The global GI services market is driven by increasing prevalence of GI diseases, rising geriatric population, and increasing government support for the development of the market. Moreover, Increasing healthcare expenditure and cost-effectiveness of the method have also contributed to the growth of the market. On the other hand, availability of alternative therapies and limited applications of the treatment have hampered the growth of the market. The global GI series market is expected to grow at a CAGR of 4.5% during the forecasted period 2017-2023.

Request Free Sample @ https://www.marketresearchfuture.com/sample_request/826

Upper Gastrointestinal (GI) Series Market Segmentation

Global upper GI series market is segmented on the basis of test types, into standard barium upper GI series and double-contrast upper GI series. On the basis of imaging materials, the market is segmented into barium swallow, barium meal, and barium follow-through. On the basis of applications, the market is segmented into esophageal reflux, esophageal varices, ulcers, hiatal hernias and others. On the basis of end users, the market is segmented: hospitals, clinics & laboratories, and other

Upper Gastrointestinal (GI) Series Market Regional Analysis

America dominates the global upper GI series market due to the presence of well-developed healthcare sector, a large number of patients suffering from GI tract diseases, and increasing aging population. Europe is the second largest market, which is followed by Asia Pacific. Whereas, Asia Pacific is the fastest growing market. Approximately, more than 30 million people are suffering from acute or chronic digestive disease conditions. In Asia Pacific, India and China are the major contributors, on the other hand, the Middle East & Africa has the lowest share in the GI series market due to limited development in the healthcare sector.

Upper Gastrointestinal (GI) Series Market Key Players

The major key player for the global upper GI series market are GastroIntestinal Specialists LLC. (UK), Eisai Co., Ltd (Japan), Cadila Pharmaceuticals Limited (India), Purdue Pharma L.P. (US), Alfa Wassermann SPA (Germany), Novadaq Technologies Inc. (Canada), GE, Healthcare (US), AstraZeneca (UK), Ironwood Pharmaceuticals Inc. (US) and others.

Global upper GI series market is a competitive market due to constant pressure to launch new products and cost-effective methods; many companies are investing in research and development of the products.

Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan and has launched number of product used as contrast media.  The company has announced its partnership with AJINOMOTO CO.,INC. for the establishment of gastrointestinal specialty EA Pharma Co., Ltd.

GE Healthcare one of the leading American multinational company headquartered in US. It is the manufacturer and distributor of diagnostic imaging agents. OMNISCAN and VISIPAQUE are the major products of the company. Recently company has launch Clariscan, which is a macrocyclic agent for the effective visualization of abnormalities in the brain, spine and associated tissues.

Access Report Details @ https://www.marketresearchfuture.com/reports/upper-gi-series-market-826

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: www.marketresearchfuture.com/reports/upper-gi-series-market-826